このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Myriad Genetics マネジメント

マネジメント基準チェック /24

Myriad Genetics'の CEO はPaul Diazで、 Aug2020年に任命され、の在任期間は 3.83年です。の年間総報酬は$ 12.11Mで、 9%給与と91%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.38%を直接所有しており、その価値は$ 7.97M 。経営陣と取締役会の平均在任期間はそれぞれ2.4年と4.1年です。

主要情報

Paul Diaz

最高経営責任者

US$12.1m

報酬総額

CEO給与比率	9.0%
CEO在任期間	3.8yrs
CEOの所有権	0.4%
経営陣の平均在職期間	2.4yrs
取締役会の平均在任期間	4.3yrs

経営陣の近況

Recent updates

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 33% Discount?

Jun 05

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

May 11

Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report

May 09

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Mar 28

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Feb 02

Myriad Genetics receives expanded coverage in Japan for breast cancer diagnostic system

Aug 25

Are Investors Undervaluing Myriad Genetics, Inc. (NASDAQ:MYGN) By 50%?

Aug 05

Myriad Genetics Q2 2022 Earnings Preview

Aug 03

Myriad Genetics touts study results of GeneSight test on depression remission rates

Jul 12

CEO報酬分析

Myriad Genetics の収益と比較して、Paul Diaz の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$235m
Dec 31 2023	US$12m	US$1m	-US$263m
Sep 30 2023	n/a	n/a	-US$274m
Jun 30 2023	n/a	n/a	-US$248m
Mar 31 2023	n/a	n/a	-US$146m
Dec 31 2022	US$11m	US$1m	-US$112m
Sep 30 2022	n/a	n/a	-US$77m
Jun 30 2022	n/a	n/a	-US$18m
Mar 31 2022	n/a	n/a	-US$8m
Dec 31 2021	US$13m	US$1m	-US$27m
Sep 30 2021	n/a	n/a	-US$57m
Jun 30 2021	n/a	n/a	-US$97m
Mar 31 2021	n/a	n/a	-US$148m
Dec 31 2020	US$16m	US$383k	-US$224m

報酬と市場: Paulの総報酬 ($USD 12.11M ) は、 US市場 ($USD 5.64M ) の同規模の企業の平均を上回っています。

報酬と収益: Paulの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Paul Diaz (62 yo)

3.8yrs

在職期間

US$12,108,359

報酬

Mr. Paul J. Diaz serves as the Member of Advisory Board at Thornton Capital, LLC. He has been the Chief Executive Officer, President and Director of Myriad Genetics, Inc. since August 13, 2020. He serves a...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Paul Diaz	CEO, President & Director	3.8yrs	US$12.11m	0.38% $ 8.2m
Samraat Raha	Chief Operating Officer	less than a year	US$5.02m	データなし
Dale Muzzey	Chief Scientific Officer	2.4yrs	US$2.23m	0.12% $ 2.6m
Mark Verratti	Chief Commercial Officer	6.8yrs	US$2.88m	0.33% $ 7.1m
Scott Leffler	Chief Financial Officer	less than a year	データなし	データなし
Natalie Munk	Principal Accounting Officer	2yrs	データなし	0.049% $ 1.1m
Kevin Haas	Chief Technology Officer	3.3yrs	US$1.64m	0.15% $ 3.2m
Matthew Scalo	Senior Vice President of Investor Relations	no data	データなし	データなし
Justin Hunter	Interim General Counsel & Corporate Secretary	3.3yrs	データなし	データなし
Glenn Farrell	Senior VP & Chief Marketing Officer	1.5yrs	データなし	データなし
Shereen Solaiman	Chief People Officer	1.3yrs	データなし	0.0032% $ 68.4k
Patrick Burke	Executive Vice President of Strategy & Innovation	3.1yrs	データなし	データなし

2.4yrs

平均在職期間

50yo

平均年齢

経験豊富な経営陣: MYGNの経営陣は経験豊富であると考えられます ( 2.4年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Paul Diaz	CEO, President & Director	3.8yrs	US$12.11m	0.38% $ 8.2m
Paul Bisaro	Independent Director	1.7yrs	US$258.48k	0.027% $ 584.3k
Lee Newcomer	Independent Director	4.8yrs	US$447.99k	0.074% $ 1.6m
Daniel Skovronsky	Independent Director	3.9yrs	US$433.49k	0.078% $ 1.7m
Colleen Reitan	Independent Director	4.8yrs	US$443.49k	0.080% $ 1.7m
Heinrich Dreismann	Independent Director	14yrs	US$443.49k	0.13% $ 2.8m
S. Phanstiel	Independent Chair of the Board	14.8yrs	US$563.49k	0.16% $ 3.5m
Rashmi Kumar	Independent Director	3.8yrs	US$433.49k	0.076% $ 1.7m

4.3yrs

平均在職期間

63.5yo

平均年齢

経験豊富なボード: MYGNの取締役会は経験豊富であると考えられます ( 4.1年の平均在任期間)。

Myriad Genetics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

CEO, President & Director recently sold US$5.7m worth of stock

CEO, President & Director notifies of intention to sell stock

Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024

Myriad Genetics, Inc. Announces Chief Financial Officer Changes

Executive VP notifies of intention to sell stock

Myriad Genetics, Inc. Appoints Samraat S. Raha as Chief Operating Officer, Effective as of December 11, 2023

Recent updates

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 33% Discount?

CEO, President & Director recently sold US$5.7m worth of stock

CEO, President & Director notifies of intention to sell stock

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Myriad Genetics, Inc. to Report Q1, 2024 Results on May 07, 2024

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Consensus EPS estimates upgraded to US$0.93 loss

Price target increased by 8.9% to US$24.50

Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024

Full year 2023 earnings: EPS misses analyst expectations

Myriad Genetics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Myriad Genetics' Strategic Growth Fuels Bullish Outlook

Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024

Myriad Genetics, Inc. (NasdaqGS:MYGN) agreed to acquire Select assets of Intermountain Precision Genomics.

Myriad Genetics, Inc. Announces Chief Financial Officer Changes

Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price

Consensus EPS estimates fall by 21%, revenue upgraded

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New minor risk - Shareholder dilution

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Myriad Genetics, Inc. Provides Financial Guidance for 2023 and 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP notifies of intention to sell stock

Myriad Genetics, Inc. Appoints Samraat S. Raha as Chief Operating Officer, Effective as of December 11, 2023

Myriad Genetics Appoints Sam Raha as Chief Operating Officer, Effective December 11, 2023

Myriad Genetics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Price target decreased by 8.2% to US$21.67

Bernstein Litowitz Berger & Grossmann LLP Proposes Settlement of Class Action Involving Persons Who Purchased or Acquired Myriad Genetics, Inc. Common Stock

Insufficient new directors

Consensus EPS estimates fall by 52%

Myriad Genetics Announces Enhancements to the Genesight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status

Is Myriad Genetics (NASDAQ:MYGN) Using Debt Sensibly?

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2023

Myriad Genetics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Myriad Genetics, Inc. Announces Inclusion of Breast Density to Myrisk(R) with Riskscore(R) Breast Cancer Risk Assessment

Independent Director notifies of intention to sell stock

Myriad Genetics, Inc. Appoints Adam Brufsky as Scientific Advisor

Consensus EPS estimates fall by 27%, revenue upgraded

Myriad Genetics, Inc. Revises Earnings Guidance for the Full Year of 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 7.7% to US$21.72

Calculating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)

Chief Operating Officer notifies of intention to sell stock

Chief Operating Officer notifies of intention to sell stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 24%

Executive VP notifies of intention to sell stock

Myriad Genetics, Inc. Hires Senior Leaders to Advance Commercial Growth Plans

Myriad Genetics, Inc. announces Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

High number of new directors

Price target decreased to US$20.44

Myriad Genetics Announces Urosuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-Driven Medical Information

Consensus EPS estimates fall by 103%

Price target decreased to US$22.19

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Myriad Genetics, Inc. (NasdaqGS:MYGN) acquired Gateway Genomics, LLC for approximately $110 million.

Myriad Genetics, Inc. Elects Paul M. Bisaro as New Board Member

High number of new directors

Myriad Genetics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Myriad: Trying To Find Its Footing In An Evolving Industry

Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer

Myriad Genetics receives expanded coverage in Japan for breast cancer diagnostic system

Price target increased to US$24.36

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

マネジメント基準チェック /24